Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the original drug. Cheaper competition to off-patent Advair has been ...

Viatris (VTRS) stock surges after Q3 earnings beat expectations with strong revenue growth and optimistic revenue outlook for ...

Mylan’s Copaxone (glatiramer) generic hits Teva where it hurts as it has been approved at both the daily 20mg dose, or the 40mg thrice weekly dose that most patients have switched to.

A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...

Pharmaceutical company Viatris (VTRS 13.52%) reported third-quarter 2024 financial results on Thursday, Nov. 7, that topped ...

Well, that was fast. It took Gov. Jim Justice all of one day after winning a seat in the U.S. Senate to play an exclusive game of political nepotism, appointing his wife, Cathy, to a nine-year term on ...

We may not be the first wave launcher in the US, but we have plans." Natco and Mylan have also collaborated on the ...

ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, ...

Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.

DUBLIN, Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2024 ...

Viatris (VTRS) Company Description: Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and ...